期刊文献+

基质金属蛋白酶-9在高血压大鼠血管重塑中表达及替米沙坦的干预作用

Expression of MMP-9 and the intervention effect of telmisartan on vascular remodeling of 2K1C Hypertension Rats
原文传递
导出
摘要 目的 探讨基质金属蛋白酶-9(MMP-9)在双肾一夹型高血压大鼠血管重塑中的表达及其可能的凋节机制.方法 将雄性wistar大鼠随机分成三组,假手术对照组(n=10),双肾一夹型模型组(n=10),替米沙坦(telmisartan)组,即治疗组(n=7),治疗组给予每天灌胃,三组均在术后每周监测血压,8周后处死大鼠取胸主动脉与颈总动脉作形态学观察,免疫组化法检测颈总动脉与胸主动脉MMP-9的蛋白表达.结果 与对照组相比,模型组血压明显升高(P<0.05),颈总动脉与胸主动脉模型组管壁增厚,MMP-9表达显著增加.治疗8周后,治疗组血压明显降低,管壁变薄,MMP-9表达减少.结论 MMP-9可能与高血压血管重塑有关,替米沙坦通过降低血压抑制血管中MMP-9的表达,并改善血管重塑. Objective To explore the expression and mechanisms of MMP-9 in vascular remodeling of two-kidney and one-cliped hypertension rats. Methods Male Wistar rats were randomly divided into sham operation group( n = 10), two-kidney and one-clip model (2KIC) group ( n = 10) and telmisartan group ( n = 7 ). Telmisartan group were injected with telmisartan every day. The blood pressure was determined every week. The morphologic change of carotid artery and thoracic aorta was observed with HE stainning 8 weeks after treatment with telmisartan.Arteries was performed to evaluate the expression of MMP-9 with immunohistochemisty. Results The blood pressure,vessel wall,and the expression of MMP-9 in model group were significantly higher than that of control group.Telmisartan nearly normalized arterial pressure and suppressed all these changes. Conclusion MMP-9 was related to vascular remodeling and Telmisartan could regulate vascular remodeling in 2-kidney and 1-cliped hypertension rats by inhibiting the pathway of MMP-9.
出处 《中国基层医药》 CAS 2010年第24期3346-3347,共2页 Chinese Journal of Primary Medicine and Pharmacy
关键词 基质金属蛋白酶9 双肾一夹型 高血压 血管重塑 替米沙坦 MMP-9 2K1 C, Hypertension Vascular Remodeling Telmisartan
  • 相关文献

参考文献9

二级参考文献27

  • 1谢柏如,周国维.国产和进口缬沙坦治疗原发性高血压疗效比较[J].中国实用医药,2007,2(33):9-10. 被引量:9
  • 2崔淑兰,李果明,杨健,赵玉兰.伊贝沙坦治疗高血压病的疗效及对血管内皮功能的影响[J].中国基层医药,2004,11(5):527-528. 被引量:3
  • 3黄晓真,黄梅,张梅,张运.卡维地洛对原发性高血压患者血管内皮功能的干预作用[J].中国基层医药,2004,11(12):1420-1421. 被引量:2
  • 4冯润川,潘华,许丁空,陈富荣.替米沙坦和福辛普利对高血压左室肥厚患者血浆内皮素和一氧化氮浓度的影响[J].江苏医药,2007,33(4):350-352. 被引量:6
  • 5[1]Nobukazu Ishizaka, Junichi Taguchi, Yukiokimura, et al. Effects of a single local administration of Cilostazol on neointimal formation in balloon injured rat carotid artery. Atheroslerosis, 1999, 142:41-46
  • 6[2]Lefkovits J, Topol EJ. Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention. Progress in Cardiov Disease, 1997,40 (2): 141-158
  • 7[3]Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res, 1995, 77:863-868
  • 8[4]Zaltsman AB, George SJ, Newby AC. Increased secretion of tissue inhibitors of metalloproteinases 1 and 2 from the aortas of cholesterol fed rabbits partially counterbalances increased metalloproteinase activity. Arterioscler Thromb Vasc Biol,1999, 19:1 700-707
  • 9[5]Take S, Matsutani M, Ueda H, et al. Effect of Cilostazol in preventing resteoosis after percutaneous transhuminal coronary angioplasty. Am J Cardio, 1997,79:1097
  • 10Pearson TA,Mensah GA,Alexander RW.Markers of inflammation and cardiovascular disease:application to clinical and public health practice:A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American HeartAssociatio.Circulation,2003,107(3):499-511.

共引文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部